Abstract
Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway by PI3K/mTOR dual inhibitors provides a promising new approach to the treatment of cancers. In this Letter, we identified structurally novel and potent PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives. Their synthesis and structure-activity relationships are reported.
Keywords:
Anti-tumor activity; Dual inhibitor; Mammalian target of rapamycin; Phosphoinositide 3-kinase.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Crystallography, X-Ray
-
Dose-Response Relationship, Drug
-
Humans
-
Models, Molecular
-
Molecular Structure
-
Phosphatidylinositol 3-Kinases / metabolism
-
Phosphoinositide-3 Kinase Inhibitors*
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Pyrimidines / chemical synthesis
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology*
-
Structure-Activity Relationship
-
TOR Serine-Threonine Kinases / antagonists & inhibitors*
-
TOR Serine-Threonine Kinases / metabolism
Substances
-
2-amino-4-methylpyrido(2,3-d)pyrimidine
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Kinase Inhibitors
-
Pyrimidines
-
TOR Serine-Threonine Kinases